Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years.

Autor: French JA; New York University Comprehensive Epilepsy Center, New York, New York, USA., Cleary E; UCB Pharma, Morrisville, North Carolina, USA., Dlugos D; Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia, Perelman, Philadelphia, Pennsylvania, USA., Farfel G; Zogenix, a UCB Company, Emeryville, California, USA., Farrell K; Research and New Therapies Program, Epilepsy Foundation of America, Maryland, USA., Gidal B; University of Wisconsin School of Pharmacy, Madison, Wisconsin, USA., Grzeskowiak CL; Research and New Therapies Program, Epilepsy Foundation of America, Maryland, USA., Gurrell R; Cerevel Therapeutics, Cambridge, Massachusetts, USA., Harden C; Clinical Development Division, Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada., Stalvey TJ; Stalvey Consulting, Dripping Springs, Texas, USA., Tsai J; Ovid Therapeutics, New York, New York, USA., Wirrell EC; Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Blum D; Consultant, Santa Barbara, California, USA., Fountain N; Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.

Publikováno v: Epilepsia [Epilepsia] 2022 Oct; Vol. 63 (10), pp. 2664-2670. Date of Electronic Publication: 2022 Aug 12.

Pharmacology in translation: the preclinical and early clinical profile of the novel alpha 2/3 functionally selective GABA(A) receptor positive allosteric modulator PF-06372865

Autor: Nickolls, S.A., Gurrell, R., Amerongen, G. van, Kammonen, J., Cao, L.S., Brown, A.R., Stead, C., Mead, A., Watson, C., Hsu, C., Owen, R.M., Pike, A., Fish, R.L., Chen, L.G., Qiu, R.L., Morris, E.D., Feng, G., Whitlock, M., Gorman, D., Gerven, J. van, Reynolds, D.S., Dua, P., Butt, R.P.

Publikováno v: British Journal of Pharmacology, 175(4), 708-725

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c098ce396adb3428abe3f8a1266b5884
https://doi.org/10.1111/bph.14119

Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABA A -Positive Allosteric Modulator PF-06372865 in Healthy Volunteers.

Autor: Gurrell R; Cerevel Therapeutics, LLC, Boston, Massachusetts, USA., Whitlock M; Pfizer Inc., Granta Park, Cambridge, UK., Wei H; Pfizer Inc., Shanghai, China., Shen Z; Pfizer Inc., San Diego, California, USA., Ogden A; Pfizer Inc., Groton, Connecticut, USA.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Jul; Vol. 10 (7), pp. 756-764. Date of Electronic Publication: 2021 Jan 19.

Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy.

Autor: Sun, Huiyan¹ (AUTHOR), Wang, Xinxia¹ (AUTHOR), Li, Yongqiang² (AUTHOR), Shen, Yingzhi¹ (AUTHOR), Zhang, Lin¹ (AUTHOR), Xu, Yingjie¹ (AUTHOR), Liu, Junling^1,2 (AUTHOR) liujl@shsmu.edu.cn, Fan, Xuemei¹ (AUTHOR) liujl@shsmu.edu.cn

Publikováno v: Pharmaceutics. Jul2024, Vol. 16 Issue 7, p938. 20p.